Skip to main content

Clinical trial EORTC 1209-EnTF

A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy

Organ Thyroïd
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor EORTC
EudraCT Identifier 2012-004295-19
Inclusion criteria At least 1 or 2 prior lines of treatment
Last update